Literature DB >> 28456874

Pulmonary Artery Dimensions as a Prognosticator of Transplant-Free Survival in Scleroderma Interstitial Lung Disease.

James Benjamin Gleason1, Krunal B Patel2, Felix Hernandez2, Anas Hadeh2, Kristin B Highland3, Franck Rahaghi2, Jinesh P Mehta2.   

Abstract

BACKGROUND: Systemic sclerosis is a chronic debilitating autoimmune disease characterized by endothelial dysfunction and multi-organ fibrosis. Interstitial lung disease, a common manifestation of SSc, is termed scleroderma-related interstitial lung disease (SSc-ILD) and along with pulmonary hypertension contributes to a majority of deaths in SSc. SSc-ILD patients frequently develop pulmonary hypertension, which prognosticates a poorer outcome. We investigated pulmonary artery dimensions as an outcome predictor in patients with SSc-ILD.
METHODS: A retrospective chart review abstracting data from SSc-ILD patients evaluated at a large tertiary care center was performed. HRCT imaging was reviewed and pulmonary artery (PA) and ascending aorta (Ao) diameters were measured for calculation of the PA:Ao ratio. Additionally, demographics, vital signs, spirometric parameters, comorbidities, and mean pulmonary artery pressures were collected when available. Outcome analysis with lung transplant or death events within 4 years based on pulmonary artery size as well as PA:Ao ratio was performed.
RESULTS: 70 SSc-ILD patients were identified. Mean pulmonary artery diameter and PA:Ao ratio was 31.17 and 1.07 mm, respectively. Patients with a pulmonary artery diameter ≥32 mm had higher risk of lung transplantation or death (p < 0.001) within 4 years. Patients with a PA:Ao ratio ≥1.1 also had higher risk of lung transplantation or death (p < 0.001) within 4 years. Unadjusted outcomes analyses also identified PA:Ao ratio ≥1.1 as an independent outcome predictor (hazard ratio 3.30, p < 0.001). CONCLUSIONS/CLINICAL IMPLICATIONS: In SSc-ILD patients, a PA:Ao ratio ≥1.1 is associated with higher risk of lung transplant or death. These data suggest that PA:Ao dimension may be used for prognostication in SSc-ILD.

Entities:  

Keywords:  Interstitial lung disease; Mortality; Pulmonary artery; Pulmonary hypertension; Scleroderma; Systemic sclerosis

Mesh:

Year:  2017        PMID: 28456874     DOI: 10.1007/s00408-017-0005-6

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  33 in total

1.  Clinical differences between idiopathic and scleroderma-related pulmonary hypertension.

Authors:  Micah R Fisher; Stephen C Mathai; Hunter C Champion; Reda E Girgis; Traci Housten-Harris; Laura Hummers; Jerry A Krishnan; Fredrick Wigley; Paul M Hassoun
Journal:  Arthritis Rheum       Date:  2006-09

2.  Prediction of pulmonary hypertension in patients with or without interstitial lung disease: reliability of CT findings.

Authors:  Esam H Alhamad; Ahmad A Al-Boukai; Feisal A Al-Kassimi; Hussam F Alfaleh; Mostafa Q Alshamiri; Abdulaziz H Alzeer; Hadil A Al-Otair; Gehan F Ibrahim; Shaffi A Shaik
Journal:  Radiology       Date:  2011-05-25       Impact factor: 11.105

3.  Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients.

Authors:  Wander O Villalba; Percival D Sampaio-Barros; Mônica C Pereira; Elza M F P Cerqueira; Cid A Leme; João F Marques-Neto; Ilma A Paschoal
Journal:  Chest       Date:  2007-01       Impact factor: 9.410

4.  Relationship of main pulmonary artery diameter to pulmonary arterial pressure in scleroderma patients with and without interstitial fibrosis.

Authors:  Robert K McCall; James G Ravenel; Paul J Nietert; Aleksandra Granath; Richard M Silver
Journal:  J Comput Assist Tomogr       Date:  2014 Mar-Apr       Impact factor: 1.826

Review 5.  Imaging in pulmonary hypertension.

Authors:  Irene M Lang; Christina Plank; Roela Sadushi-Kolici; Johannes Jakowitsch; Walter Klepetko; Gerald Maurer
Journal:  JACC Cardiovasc Imaging       Date:  2010-12

6.  Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters.

Authors:  A Fischer; J J Swigris; M B Bolster; L Chung; M E Csuka; R Domsic; T Frech; M Hinchcliff; V Hsu; L K Hummers; M Gomberg-Maitland; S C Mathai; R Simms; V D Steen
Journal:  Clin Exp Rheumatol       Date:  2014-11-04       Impact factor: 4.473

7.  Isolated diffusing capacity reduction in systemic sclerosis.

Authors:  V D Steen; G Graham; C Conte; G Owens; T A Medsger
Journal:  Arthritis Rheum       Date:  1992-07

8.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

9.  Predictors of survival in systemic sclerosis (scleroderma).

Authors:  R D Altman; T A Medsger; D A Bloch; B A Michel
Journal:  Arthritis Rheum       Date:  1991-04

10.  Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry.

Authors:  Lorinda Chung; Robyn T Domsic; Bharathi Lingala; Firas Alkassab; Marcy Bolster; M E Csuka; Chris Derk; Aryeh Fischer; Tracy Frech; Daniel E Furst; Mardi Gomberg-Maitland; Monique Hinchcliff; Vivien Hsu; Laura K Hummers; Dinesh Khanna; Thomas A Medsger; Jerry A Molitor; Ioana R Preston; Elena Schiopu; Lee Shapiro; Richard Silver; Robert Simms; John Varga; Jessica K Gordon; Virginia D Steen
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-03       Impact factor: 5.178

View more
  1 in total

1.  Larger pulmonary artery to ascending aorta ratios are associated with decreased survival of patients undergoing pulmonary endarterectomy.

Authors:  Panja M Boehm; Stefan Schwarz; Jürgen Thanner; Cecilia Veraar; Mario Gerges; Christian Gerges; Irene Lang; Paul Apfaltrer; Helmut Prosch; Shahrokh Taghavi; Walter Klepetko; Hendrik Jan Ankersmit; Bernhard Moser
Journal:  JTCVS Open       Date:  2022-02-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.